OncoMatch/Clinical Trials/NCT03400826
Effects of Simvastatin on Uterine Leiomyoma Size
Is NCT03400826 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Simvastatin 40mg for fibroid uterus.
Treatment: Simvastatin 40mg — The study aims to study the effect of simvastatin on the size of uterine fibroids.
Check if I qualifyExtracted eligibility criteria
Lab requirements
Blood counts
Hemoglobin ≤ 6 g/dL [excluded]
Liver function
Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels (elevation of aspartate transaminase and/or alanine transaminase > 2 s.d. above the normal range at screening visit) [excluded]
Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels.( elevation of aspartate transaminase and/or alanine transaminase > 2 s.d. above the normal range at screening visit); Hemoglobin ≤ 6 g/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Johns Hopkins Hospital · Baltimore, Maryland
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify